CClinicalTrials.gg
Sign In
Status unknownNCT03299647Updated Oct 13, 2017

Effects of Polyunsaturated Fatty Acids on the Visual Memory of Children With Attention Deficit Hyperactivity Disorder

An observational study in Attention-deficit/Hyperactivity Disorder, sponsored by National Taiwan University Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 7 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-13.

Sponsored by National Taiwan University Hospital · Observational

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
70
Ages
7 Years to 18 Years
Sex
All
01

Study summary

The investigators anticipate to identify specific polyunsaturated fatty acids that show significant differences between ADHD and control groups. In addition, these findings may offer more biological understanding in explaining the relationship between polyunsaturated fatty acids and visual memory among children with ADHD. The results will significantly contribute to the knowledge of the pathophysiological mechanisms of ADHD, especially the polyunsaturated fatty acids related to the behavioral/visual memory deficits of ADHD.

Read the detailed description

Because attention deficit hyperactivity disorder (ADHD) is an early onset and long-term impairing disorder with tremendous impact on individuals, families, and societies, detection and diagnosis are very important for ADHD. According to the investigators' previous work, children with ADHD have visual memory deficits as well as inattentive deficits. Previous studies show that polyunsaturated fatty acids are associated with cognitive problems in children. Analyzing differences in polyunsaturated fatty acids between children with ADHD and healthy controls could provide insight into underlying disease pathology of cognitive deficits. In this one-year project, the researchers will perform an analysis of polyunsaturated fatty acids in serum to identify potential biomarkers for the visual memory deficits of ADHD.

The purpose of this study is to:

  1. To identify the specific polyunsaturated fatty acids of ADHD symptoms;
  2. To identify the relationship between specific polyunsaturated fatty acids and visual memory deficits of ADHD.

This is a one-year project. After careful calculation of sample size, the study will recruit 35 children with ADHD, aged 7-18, and 35 healthy controls with matched age, sex and BMI. The investigators will quantify the polyunsaturated fatty acids in serum. The behavioral measures include ADHDRS-IV, SNAP-IV, CBCL, CGI-ADHD-S, SAICA, and Family APGAR-C. The Cambridge Neuropsychological Test Automated Battery (CANTAB) will be used to assess the visual memory of all participants. Conditional logistic regression and partial least squares discriminant analysis will be applied to identify significant polyunsaturated fatty acids for ADHD and visual memory deficits.

02

Conditions studied

  • Attention-deficit/Hyperactivity Disorder

Keywords

  • Attention-deficit/hyperactivity disorder
  • behavioral deficits
  • cognitive function
  • polyunsaturated fatty acids
  • visual memory
03

Who can participate

Ages eligible
7 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The researchers plan to recruit 35 ADHD subjects and 35 control subjects.

Inclusion criteria

Patients with ADHD are eligible to be included in this study only if they meet all of the following criteria:

  1. Patients will be outpatients who are between 7 and 18 years of age.
  2. Patients must have ADHD that meet the Diagnostic and Statistical Manual of Mental disorders, 5th edition (DSM-V) disease diagnostic criteria assessed by the investigator's clinical evaluation, as well as confirmed by the Chinese version of the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiological Version (K-SADS-E).
  3. Patients must have a Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) score > 4 at baseline.
  4. Patients must be psychotropic drug-naïve. Patients will be considered to be drug-naïve if they have never received medications specifically to treat ADHD.
  5. Patients and parents (or legal representative) must have a degree of understanding sufficient to be able to communicate suitably with the investigator.
  6. Patients must be of normal intelligence in the judgment of the investigator. Normal intelligence is defined as achieving a score of 80 or more when IQ testing is administrated.
  7. Patients must have been judged by the investigator to be reliable to keep appointments for clinic visits and all tests, including neuropsychological testing and venipunctures.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from the study if they meet any of the following criteria:

  1. Patients with current or past history of schizophrenia, schizoaffective Disorder, organic psychosis, bipolar I or II disorder, autism, or autism spectrum disorder. Other comorbid psychiatric disorders are not excluded if the ADHD symptoms are the primary source of impairment for the patient.
  2. Patients with a history of any seizure disorder (other than febrile convulsion) or patients who are taking anticonvulsants for seizure control.
  3. Patients have been at serious suicidal risk, determined by the investigator.
  4. Patients with a history of alcohol or drug abuse within the past 3 months, or who are currently using alcohol, drugs of abuse, or any described or over-the-counter medication in a manner that the investigator considers indicative of abuse.
  5. Patients with cardiovascular disease or other conditions that could be aggravated by an increased heart rate or increased blood pressure.
  6. Patients who are likely to need Chinese medicine or health-food supplements that have central nervous system activity.
04

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
70 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • ADHD group

    Subjects with clinical diagnosis of ADHD according to the DSM-V criteria

  • TD group

    Typically development controls without lifetime diagnosis with ADHD

05

What researchers measure

Primary outcomes

  1. Psychiatric interview

    Subjects will be interviewed by Chinese Version of the Kiddie Epidemiologic version of the Schedule for Affective Disorders and Schizophrenia (K-SADS-E)

    Time frame: 1 hour

Secondary outcomes

  1. Continuous Performance Test (CPT)

    The main feature of CPT is that a rapid presentation of visual or auditory stimuli over a definite period of time. The subjects respond by pressing a switch button in response to a critical stimulus.

    Time frame: 15 minutes

  2. Wechsler Intelligence Scale for Children-3rd edition (WISC-III)

    The WISC-III is composed of 13 subtests to test children's cognitive ability of different dimensions, which are grouped into two scores: performance IQ score (7 subtests: Picture Completion, Block Design, Object Assembly, Picture Arrangement, Coding, Symbol Search and Mazes subtests) and verbal IQ score (Information, Comprehension, Arithmetic, Similarities, Digit Span and Vocabulary subtests) (Allen and Thorndike 1995).

    Time frame: 1.5 hours

  3. Cambridge Neuropsychological Test Automated Batteries (CANTAB)

    The CANTAB is a computer-administered, nonverbal (visually-presented) set of neuropsychological tasks developed at the University of Cambridge.

    Time frame: 1.5 hours

06

Study locations

1 of 1 sites recruiting
  • National Taiwan Univeristy Hospital
    Taipei, Taiwan
    • Chi-Yung Shang, MD · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03299647
Lead sponsor
National Taiwan University Hospital
Responsible party
Sponsor
First posted
Oct 3, 2017
Start date
Jul 31, 2017
Primary completion
Jul 30, 2018 (estimated)
Completion
Jul 30, 2018 (estimated)
Last update
Oct 13, 2017

Study contacts

Chi-Yung Shang, MD
Contact
cyshang@ntu.edu.tw
886-2-23123456 Ext. 66965
Chi-Yung Shang, MD
principal investigator · Dept of Psychiatry, National Taiwan University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hyperkinesis→

Other studies from this sponsor

National Taiwan University Hospital

Start the discussion